| Identification | Back Directory | [Name]
1-(2-Diphenylmethoxyethyl)-4-(3-phenylpropyl)piperazinedihydrochloride | [CAS]
76778-22-8 | [Synonyms]
CS-1257
GBR 12935
GBR12935;GBR-12935
GBR 12935 mesylate
GBR-12935 free base
(DIPHENYLMETHOXY)GBR - 12935
1-[2-(Diphenylmethoxy)ethyl]-4-(3-phenylpropyl)
1-(2-benzhydryloxyethyl)-4-(3-phenylpropyl)piperazine
1-Hydrocinnamyl-4-[2-(diphenylmethoxy)ethyl]piperazine
1-[2-(Diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine
Piperazine, 1-(2-(diphenylmethoxy)ethyl)-4-(3-phenylpropyl)-
1-(2-(Benzhydryloxy)ethyl)-4-(3-phenylpropyl)piperazine Maleate
1-(2-(diphenylMethoxy)ethyl)-4-(3-phenylpropyl)piperazine Maleate
GBR-12935, 1-(2 -(diphenylMethoxy) ethyl) -4-(3-phenylpropyl) piperazine
N-[3-tert-Butyl-1-(4-Methylphenyl)-1H-pyrazol-5-yl]-N-[4-[2-(4-Morpholinyl)ethoxy]naphthalen-1-yl]urea | [Molecular Formula]
C28H34N2O | [MDL Number]
MFCD00600387 | [MOL File]
76778-22-8.mol | [Molecular Weight]
414.58 |
| Chemical Properties | Back Directory | [Boiling point ]
540.6±50.0 °C(Predicted) | [density ]
1.067±0.06 g/cm3(Predicted) | [storage temp. ]
Desiccate at -20°C | [solubility ]
Soluble in DMSO | [form ]
Powder | [pka]
7.55±0.10(Predicted) |
| Hazard Information | Back Directory | [Uses]
GBR 12935 is a potent, and selective dopamine reuptake inhibitor, with the binding constant (Kd) of 1.08 nM in COS-7 cells. GBR 12935 stimulates the locomotion activity in different mice strains but fails to induce stereotypy. Thus, GBR 12935 also prevents the d-Fenfluramine-induced head-twitch response in mice[1][2][3][4]. | [Definition]
ChEBI: An N-alkylpiperazine that consists of piperazine bearing 2-(benzhydryloxy)ethyl and 3-phenylpropyl groups at positions 1 and 4 respectively. Potent and selective inhibitor of dopamine uptake (KD = 5.5 nM in rat stria
al membranes). | [Biological Activity]
Potent and selective inhibitor of dopamine uptake (K D = 5.5 nM in rat striatal membranes). | [in vivo]
GBR 12935 (1-32 mg/kg; repeat injection; 7 d) elevates locomotion activity to a greater extent in C57BL/6J mice than DBA/2J mice, and (10 mg/kg; injection; 7 d) results few mice sensitized to cocaine-induced stereotypy with repeated injections[3].
| Animal Model: | Adult male DBA/2J and C57BL/6J mice (22-30 g)[3] | | Dosage: | 1.0, 3.2, 10, 32 mg/kg | | Administration: | Repeat injection; for 7 days | | Result: | Elevated locomotion activity to a greater extent in C57BL/6J mice than DBA/2J mice.
No stereotypy was induced by an eighth day challenge of 10 mg/kg GBR 12935 in mice pretreated with seven dally injections of either 32 mg/kg cocaine or saline. |
| [storage]
Store at -20°C | [References]
[1] Hiroi T, et al. Specific binding of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenyl propyl) piperazine (GBR-12935), an inhibitor of the dopamine transporter, to human CYP2D6. Biochem Pharmacol. 1997 Jun 15;53(12):1937-9. DOI:10.1016/s0006-2952(97)00172-x
[2] Rahman S, et al. Negative interaction of dopamine D2 receptor antagonists and GBR 12909 and GBR 12935 dopamine uptake inhibitors in the nucleus accumbens. Eur J Pharmacol. 2001 Feb 23;414(1):37-44. DOI:10.1016/s0014-2999(01)00785-3
[3] Tolliver BK, et al. Comparison of cocaine and GBR 12935: effects on locomotor activity and stereotypy in two inbred mouse strains. Pharmacol Biochem Behav. 1994 Jul;48(3):733-9. DOI:10.1016/0091-3057(94)90340-9
[4] Darmani NA. Cocaine and selective monoamine uptake blockers (sertraline, nisoxetine, and GBR 12935) prevent the d-fenfluramine-induced head-twitch response in mice. Pharmacol Biochem Behav. 1998 May;60(1):83-90. DOI:10.1016/s0091-3057(97)00548-0 |
|
|